Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. - Wikidata - awgldk - TriplyDB

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

http://www.wikidata.org/entity/Q45900126

about

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission Quetiapine versus other atypical antipsychotics for schizophrenia Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?Antipsychotic drugs and obesity.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls Metabolic syndrome in schizophrenia.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Treatment strategies for dosing the second generation antipsychotics.Weight gain associated with taking psychotropic medication: an integrative review.Lipid effects of psychiatric medications.Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.Experimental drugs for bipolar psychosis.Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Atypical antipsychotics for the treatment of ICU delirium.Low Density Lipoprotein Receptor-Related Protein and Apolipoprotein E Expression is Altered in Schizophrenia.Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.Identification and counseling for obesity among children on psychotropic medications in ambulatory settings.

P2860

Q23913269-80457983-22B5-45A4-9A30-B33364BEE789 Q24202427-F945F37A-F0FC-46B8-894D-1F50EFA84769 Q26864342-745E3135-7FDC-4555-9CF3-8004818AF734 Q28541531-BA0E485A-1E7C-437D-93B7-B07BF1B1E5F6 Q30501289-7494D07F-A585-448F-A004-E9D444580883 Q30736365-B713D109-C4EC-42EA-BE48-BB6DA7004820 Q33622056-433B56A7-2F3B-4A06-B387-292112CF793E Q33968686-7D78DECA-6779-403F-81CE-D713E90ACAA3 Q34181934-4FB33BE4-3DB8-4963-B88B-987B6202FFC5 Q34484974-F3CE7E95-0097-47A9-9ADC-CAB08E1D35DD Q34634393-FC1E01A4-FFF8-43D8-B279-4AF2B2D02B56 Q34648940-D81DA031-D6DF-4646-9ABC-DE5CEE17ADB0 Q35156543-6FDEC3BA-7665-4503-9727-4C94D0FBCAAB Q35191252-5D0A8778-9B03-410C-B94B-D0FC50FA2F2F Q35334500-53EFC2AF-7797-4540-8E8D-E95269785504 Q35680962-23CBDC2D-58F6-46DF-9592-0354C38D840E Q35754726-6AA336B4-4918-42B9-9A64-42B17FEACA9A Q35763638-523AEAFF-A76F-4811-BAA1-968146EFA444 Q36034676-AD58806D-96A7-4468-9879-DE8B0320F5C5 Q36063735-1A84A55D-A721-43E0-8C41-86E472657F85 Q36621041-15B95868-DE35-4E92-82F4-6D08DCEB59F4 Q37043479-F2503471-AD76-449D-A417-C9D46DC82E22 Q37102229-08DEB916-6FCD-43C3-9AB5-372012FB8A2E Q37110540-AA0DF419-19FA-4D5A-B4C2-A8A29D57252D Q37236162-C0A0A84E-260F-4E8C-BB9F-CE06F4FA86D6 Q37290165-DB27E0DE-887B-4854-81CC-9AFA8B4294AC Q37760926-F035F88C-4604-458B-9B85-DF555E44D493 Q37852818-DEA77C8A-B003-4E72-B9B4-6189DD7C4DDB Q37865068-689C4A34-4827-4B74-8081-8E344A550E89 Q38066118-9CBA2DBF-6916-4697-9051-08D7AC8E9F7D Q38473090-A36BBED6-3AA5-475C-94C6-1EDD32357D27 Q38660754-73750538-FC83-49BD-A4D1-9E772260588A Q38995982-60FA4AEA-32FC-4556-93D7-07714FBCBF20 Q39209607-292C9F61-462F-457B-9AF8-1EB161719E86 Q39767297-9068320E-AA27-4355-85A9-02F2E6B202EF Q41771932-7DD77075-2590-4E7C-B199-EC51EEE00512 Q42427644-CC8E3AA8-6E88-4568-BD86-7869B05103A3 Q43613438-C19A7FE4-3B10-4D59-9278-0E544AB7B75B Q43691248-1F711E17-D029-4E16-8984-6650D74BBEEC Q44223285-1CFF6C16-137C-46EE-9F60-D22695830E8C

P2860

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

http://www.wikidata.org/entity/Q45900126

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Metabolic profiles of second-g ...... findings from the CAFE study.

@en

Metabolic profiles of second-g ...... findings from the CAFE study.

@nl

type

label

Metabolic profiles of second-g ...... findings from the CAFE study.

@en

Metabolic profiles of second-g ...... findings from the CAFE study.

@nl

prefLabel

Metabolic profiles of second-g ...... findings from the CAFE study.

@en

Metabolic profiles of second-g ...... findings from the CAFE study.

@nl

P1433

Q45900126-49507212-85AF-4FE2-BABA-545E8EC64627

P1476

Q45900126-120F2B57-7DBD-4B3B-BFE7-AC718A8AF213

P2093

Q45900126-38B3E864-7AA6-45C4-82D8-A34080336086

Q45900126-4DD1FB7B-F8A4-4F82-810B-52A9EC69B450

Q45900126-64B5F003-91D5-482D-AC30-B9C0F6A10E49

Q45900126-748D011F-9219-4F04-B5CB-5D0253B6A6D9

Q45900126-902DBE44-2462-409E-9080-A72BD9D8AA8B

Q45900126-992EEE72-297B-4722-9ACC-6E5ADC9A510D

Q45900126-F0786040-E663-467F-9B2B-50AE152769A5

Q45900126-F594BD7E-DCE5-4B83-B722-8D825F066CF7

P304

Q45900126-CD6AAD38-4EB2-4892-8991-491A8CB3CE53

P31

Q45900126-936D0BBB-CB84-4DFA-9760-4E522C07A4D8

P356

Q45900126-B2C85657-0F49-4D7E-8FF5-89A3B3DC7B3A

P407

Q45900126-22986091-83A1-42F1-9510-16876591BD39

P433

Q45900126-238CDAA0-2A1E-4C2D-9C1E-03AE610CDA62

P478

Q45900126-67F86362-60B5-421C-ACA1-2D3D25831C53

P577

Q45900126-E74FA821-8FB6-46AB-8765-9672E205061C

P5875

Q45900126-10AE1C5B-5C76-43DD-96EA-AB5C0D3E2697

P698

Q45900126-C5195F9C-1D4B-40D9-860E-F157C0B9D880

P356

J.SCHRES.2009.03.025

P1433

Schizophrenia Research

P1476

Metabolic profiles of second-g ...... findings from the CAFE study.

@en

P2093

CAFE Investigators

http://www.w3.org/2001/XMLSchema#string

Diana O Perkins

http://www.w3.org/2001/XMLSchema#string

Jayendra K Patel

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Lieberman

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Peter F Buckley

http://www.w3.org/2001/XMLSchema#string

Robert M Hamer

http://www.w3.org/2001/XMLSchema#string

Sandra Woolson

http://www.w3.org/2001/XMLSchema#string

P304

9-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SCHRES.2009.03.025

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24365288

http://www.w3.org/2001/XMLSchema#string

P698

19398192

http://www.w3.org/2001/XMLSchema#string